Stem Cell and Cancer Institute, a unit of PT Kalbe Farma, secured exclusive licensing rights to Stemedica Asia's ischemic-tolerant adult allogeneic mesenchymal and neural stem cells for use in clinical research in the Philippines, Thailand and Indonesia. The deal could be extended to additional countries in Asia.
Stemedica licenses stem cells to Kalbe Farma
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|